Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Phase I/IIa Safety Study of Subretinal Implantation of CPCB-RPE1 (Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Seeded on a Polymeric Substrate) in Subjects With Advanced, Dry Age-Related Macular Degeneration (AMD)
Authors not listed
Regenerative Patch Technologies, LLC · 2016
Abstract
The Phase I/IIa clinical trial is designed to assess the feasibility of delivery and safety of Human Embryonic Stem Cell-Derived RPE Cells on a parylene membrane (CPCB-RPE1) in patients with advanced, dry age-related macular degeneration.
Primary Objective:
• To test the safety and tolerability of CPCB-RPE1 during and after subretinal implantation in patients with geographic atrophy with evidence of involvement of the central fovea.
Secondary Objective:
• To assess visual acuity, visual field, and retinal function after CPCB-RPE1 implantation. Implanted and fellow eyes will be compared post-implantation to assess the ability of the implant to prevent disease progression.
Exploratory Objectives:
• To assess the feasibility of measuring the change in area of geographic atrophy over time using spectral domain optical coherence tomography or fundus autofluorescence.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (2016). A Phase I/IIa Safety Study of Subretinal Implantation of CPCB-RPE1 (Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Seeded on a Polymeric Substrate) in Subjects With Advanced, Dry Age-Related Macular Degeneration (AMD). <em>Regenerative Patch Technologies, LLC</em>. https://clinicaltrials.gov/study/NCT02590692
Vancouver
Anonymous. A Phase I/IIa Safety Study of Subretinal Implantation of CPCB-RPE1 (Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Seeded on a Polymeric Substrate) in Subjects With Advanced, Dry Age-Related Macular Degeneration (AMD). Regenerative Patch Technologies, LLC. 2016.
BibTeX
@misc{anon2016APhase,
title = {A Phase I/IIa Safety Study of Subretinal Implantation of CPCB-RPE1 (Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Seeded on a Polymeric Substrate) in Subjects With Advanced, Dry Age-Related Macular Degeneration (AMD)},
author = {Anonymous},
journal = {Regenerative Patch Technologies, LLC},
year = {2016},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Chinese Academy of Sciences 2018
Open access · US-GOV
Safety and Efficacy of Subretinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases
Ophthalmology 2018
Open access · OA
Progression of Geographic Atrophy in Age-related Macular Degeneration
The First Affiliated Hospital with Nanjing Medical University 2025
Open access · US-GOV
Study in Human iPSCs-derived Retinal Pigment Epithelium Cells Transplantation for Advanced (Late-stage) Age-Related Macular Degeneration
American Journal of Ophthalmology 2002
Citation only
Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration.
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus 2022
Open access · US-GOV
Treatment of Age-related Macular Degeneration Using Retinal Stem and Progenitor Cells
Drugs & Aging 2002
Citation only